 |
|
| VARIABILITY IN HUMAN DRUG RESPONSE
| |
| | |
|
|
 Proceedings of the Esteve Foundation Symposium VIII, Sitges, Spain, 7-10 October 1998
Edited by
G.T. Tucker, University of Sheffield, Section of Molecular Pharmacology and Pharmacogenetics, Division of Clinical Sciences, The Royal Hallamshire Hospital, Sheffield, UK
Included in series
International Congress, 1178
Description
Variability in Human Drug Response represents a comprehensive account of the information shared by the participants of the Esteve
Foundation's Eight Symposium held in Sitges, Spain. The Esteve Foundation which operates independently of any pharmaceutical enterprise,
organizes international multidisciplinary meetings like The Esteve Foundation Symposia whose main goal is to stimulate progress in pharmacotherapy
through scientific communication and discussion.
The 8th symposium provided a timely forum which took into account the many aspects
of variability in human drug response. The fact that every patient is different indicates the reason why the art and science of medical
diagnosis is so interesting. The diversity in treatment can be viewed both as a challenge and as an obstacle. Clinical pharmacologists
have been dealing with the challenge of understanding the many sources of variability in drug responses. With the advent of molecular
biology, its increasing impact on genetic contributions to disease and to enzyme and receptor variability, has come into focus.
The sources
of variability were classified as drug metabolism enzymes, transporters and receptors and their modulation by age, sex, race, disease
and exercise; subjective factors (perception of treatment, pain, compliance, placebo response); and behavioural influences.
A record
of the lively debate followed after every presentation.
Many questions were raised by the participant regarding the design of drugs with
new chemical entities, the pharmaceutical manipulation of the dosage and the regulatory expectations to the variability of drug dosage.
Once again, in the tradition of The Esteve Foundation Symposia, progress in pharmacotherapy have been achieved with the success of the
8th symposium.
Contents
About the Esteve Foundation. Introduction. List of participants.
Pharmacokinetic / pharmacodynamic impact of genetic polymorphism of drug
metabolizing enzymes (H.K. Kroemer, W. Siegmund). Discussion.
Clinical Aspects of Polymorphic Drug Metabolism (G.T. Tucker). Discussion.
Enzyme Inhibition and Induction - PK/PD Impact (U. Klotz, K.T. Kivistö). Discussion.
Adverse drug reactions: role of enzyme inhibition
and induction (M. Pirmohamed, B.K. Park). Discussion.
Approaches to studying the role of transporters in drug interactions in man (P.B.
Watkins). Discussion.
Genetic polymorphisms in cardiovascular disease: focus on renin angiotensin system (G.K. Davis, N.H. Naqvi). Discussion.
Pharmacogenetics of respiratory system drugs (I.P. Hall). Discussion.
Tolerance as a Modulator of Drug Response (N.L. Benowitz). Discussion.
Variability in human drug response. Age as a source of variability (M.T. Kinirons). Discussion.
Gender as a source of variability in
human pharmacokinetics and pharmacodynamics (P.Rolan, L. McKeown). Discussion.
Ethnic differences in drug response: A model for understanding
interindividual variability (A.J.J. Wood). Discussion.
Effect of disease on the pharmacokinetic and pharmacodynamic determinants of response
to diuretics (D.C. Brater). Discussion.
Effects of exercise on human drug response (M.A. van Baak). Discussion.
Benefit risk evaluation
of medicinal products - an epidemiological approach (C. Martinez). Discussion.
Pain - How to standardize a subjective measure (E.A. Kalso).
Discussion.
Variable patient compliance as a source of variability in drug response (J. Urquhart). Discussion.
Placebo Response (M. Lader).
Discussion.
Pharmacogenetic basis of variation in drug dependence (E.M. Sellers et al.). Discussion.
Role of phenotyping and
genotyping in the measurement of variability in human drug response (J. Benítez). Discussion.
Population Modelling (L. Aarons).
Discussions.
Can we design drugs with low variability (D. Smith). Discussion.
Management of variability through dosage form design (P.
du Souich, A.O.S. El-Kadi, A.M. Bleau). Discussion.
Management of variability - Regulatory Aspects (T. Salmonson, J.R. Wade). Discussion.
Bibliographic & ordering Information
Hardbound, 316 pages, publication date: JUL-1999
ISBN-13: 978-0-444-82958-0
ISBN-10: 0-444-82958-X
Imprint: EXCERPTA MEDICA
Price: Order form
EUR 131
GBP 87.50
USD 131
Books and book related electronic products are priced in US dollars (USD), euro (EUR), and Great Britain Pounds (GBP). USD prices apply to the Americas and Asia Pacific. EUR prices apply in Europe and the Middle East. GBP prices apply to the UK and all other countries.
See also information about conditions of sale & ordering procedures, and links to our regional sales offices.
096/966
Last update: 26 Aug 2008
|
|
| |
| | |
|
|
| |
